

Compensation Results by NIOSH-IREP Cancer Model

Based on Claims with DR Approved and Submitted to DOL through September 1, 2023 (49,021 Claims)

Claims with a Single Primary Cancer							
Rank by Compensation Rate	NIOSH IREP Cancer Model	Compensated (PC ≥ 50%)		Not Compensated (PC < 50%)		Total Claims	
		N	%	N	%	N	%
1	Lung	3618	61.9	2230	38.1	5848	17.9
2	Non-melanoma skin-Basal Cell	1437	50.4	1414	49.6	2851	8.7
3	Chronic Myeloid Leukemia	61	47.3	68	52.7	129	0.4
4	Acute Lymphocytic Leukemia	45	40.2	67	59.8	112	0.3
5	Lymphoma & multiple myeloma	912	37.5	1523	62.5	2435	7.4
6	Liver	108	35.4	197	64.6	305	0.9
7	Chronic Lymphocytic Leukemia	124	32.4	259	67.6	383	1.2
8	Acute Myeloid Leukemia	84	32.3	176	67.7	260	0.8
9	Malignant melanoma	326	31.8	700	68.2	1026	3.1
10	Other respiratory	246	29.5	589	70.5	835	2.6
11	Leukemia, excl. CLL	49	28.0	126	72.0	175	0.5
12	Oral Cavity and Pharynx	125	19.8	505	80.2	630	1.9
13	Bone	50	15.6	271	84.4	321	1.0
14	Thyroid	72	14.3	431	85.7	503	1.5
15	Gallbladder	21	12.9	142	87.1	163	0.5
16	Stomach	64	9.1	639	90.9	703	2.2
17	Colon	117	7.2	1502	92.8	1619	5.0
18	Eye	5	6.9	67	93.1	72	0.2
19	Urinary organs, excluding bladder	56	6.2	842	93.8	898	2.7
20	Bladder	52	6.0	814	94.0	866	2.6
21	Other and ill-defined sites	5	5.0	96	95.0	101	0.3
22	All Male Genitalia	219	3.4	6196	96.6	6415	19.6
23	Connective tissue	7	3.0	227	97.0	234	0.7
24	Other endocrine glands	1	2.9	34	97.1	35	0.1
25	Esophagus	6	2.8	209	97.2	215	0.7
26	All digestive	4	2.3	168	97.7	172	0.5
27	Non-melanoma skin-Squamous Cell	18	1.5	1153	98.5	1171	3.6
28	Breast	19	1.2	1517	98.8	1536	4.7
29	Pancreas	10	1.2	808	98.8	818	2.5
30	Rectum	8	1.2	684	98.8	692	2.1
31	Ovary	1	0.6	174	99.4	175	0.5
32	Nervous system	3	0.5	581	99.5	584	1.8
33	Female Genitalia, excl. ovary	0	0.0	411	100.0	411	1.3
Subtotal for Claims with a Single Primary Cancer		7873	24.1	24820	75.9	32693	66.7
Subtotal for Claims with 2 Primary Cancers		2183	26.6	6027	73.4	8210	16.7
Subtotal for Claims with 3 Primary Cancers		1074	34.5	2036	65.5	3110	6.3
Subtotal for Claims with 4 Primary Cancers		1858	37.1	3150	62.9	5008	10.2
Subtotal for Claims with Multiple Primary Cancers		5115	31.3	11213	68.7	16328	33.3
GRAND TOTAL (ALL CLAIMS)		12988	26.5	36033	73.5	49021	100.0

The data presented on this page: may not be predictive of future results; reflect claims that were evaluated using a single primary cancer (unless otherwise noted); and, are in some cases based on a small number of cases.

The data present on this page are indicative of compensation rates for claims that have gone through dose reconstruction and do not include claims that have been awarded compensation through the Special Exposure Cohort (SEC) process. Thus, overall compensation rates for the 22 cancers that are included in the SEC may be higher.

